Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction (NCT07610577) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
United States377,753 participantsStarted 2025-11-01
Plain-language summary
This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
This study uses a series of descriptive observational analyses conducted using German and US healthcare claims data, the CMS Open Payments database, and Medicare Part D prescribing data by national provider identifier.
Patient-level analyses will use new-user cohort study designs conducted separately in German and US administrative healthcare claims databases. These analyses will evaluate temporal trends in the age- and sex-standardized initiation of clopidogrel, ticagrelor, and prasugrel among adults initiating outpatient P2Y12 inhibitor therapy after acute myocardial infarction and describe these trends in the context of the evolving evidence base and guideline recommendations. In addition, patient-level analyses will assess temporal trends in 12-month treatment costs, as well as population-level trends in major adverse cardiovascular events and bleeding-related hospitalizations among P2Y12 inhibitor initiators in Germany.
Separate US-based analyses will evaluate industry payments associated with ticagrelor and prasugrel reported in the CMS Open Payments database and provider-level prescribing patterns according to receipt of ticagrelor-associated industry payments using linked Medicare Part D prescribing data.
Eligible cohort entry dates for patient-level analyses will range from 2011 through 2024.
PATIENT-LEVEL COHORT ANALYSES Inclusion Criteria
* Adults aged ≥18 years
* Acute myocardial infarction
* Initiation of outpatient treatment with clopidogrel, ticagrelor, or…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study seems to be tracking trends in how often different blood thinners like clopidogrel, ticagrelor, and prasugrel are prescribed after a heart attack, along with their costs — so it's observational rather than a treatment trial. Does that mean it wouldn't change which medication I personally receive, and is one of these three drugs being recommended for me right now?
2Since this study is comparing the costs of these three P2Y12 inhibitors over time, does the out-of-pocket cost difference between clopidogrel, ticagrelor, and prasugrel actually matter for my treatment decision, and which one would you recommend based on my specific situation?
3This trial is no longer enrolling new participants — so is there any newer or currently active trial looking at these medications after a heart attack that might be worth discussing as an option for me?
4Given that this study is analyzing population-level prescribing patterns rather than testing a new therapy, what does the current evidence say about which of these three blood thinners tends to work best for someone with my type of heart attack and overall health profile?
5Since this is a real-world data study and not a randomized treatment trial, how should I interpret any findings that come from it — would they carry the same weight as results from a controlled clinical trial when it comes to guiding my own treatment?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Population-level trends in age- and sex-standardized proportions of clopidogrel, ticagrelor, and prasugrel initiators over time
Timeframe: 2011 to 2024
2
Population-level trends in consumer price index-adjusted net 12-month costs of clopidogrel, ticagrelor, and prasugrel over time